1. Introduction {#sec1}
===============

Deoxynivalenol (DON) is one of the most common secondary metabolites produced by *Fusarium sp.* and mainly contaminates wheat, maize and other crops in the field and during storage ([@bib35]). DON seriously threatens the health of humans and animals, as it shows enterotoxicity, immunotoxicity and teratogenicity ([@bib25]; [@bib28]). Pigs are the most sensitive species to DON and intestine is the most important target organ of DON which could induce intestinal inflammation and disrupt the intestinal barrier function ([@bib3]; [@bib4]). Ingestion of DON induces gut injury and inflammation, and affects growth performance of piglets ([@bib26]; [@bib39]; [@bib44]). Low-dose of DON (2 μM) exposure causes immunostimulation, whereas high-dose of DON (16 μM) plays as inmmunoinhibitory in porcine alveolar macrophage cells (PAMs) ([@bib29]). In addition, studies found that DON (3.875 mg/kg) affected developmental competence of ovaries and oocyte quality of female mouse, and 1.09 mM DON caused deformity in 50% of zebrafish larvae ([@bib16]; [@bib22]). On the other hand, DON can accelerate the intestinal disease of other etiologies such as colitis induced by Dextran sulfate sodium (DSS) in adult rats ([@bib36]). Pollution of DON is more common. Investigations shown that the pollution rate of DON in China is over 70% and the average pollution level is under 500 μg/kg which is below the national hygienical standard for feeds (≤1000 μg/kg, GB 13078--2017) ([@bib20]; [@bib63]). According to limit standard in China, the contamination of DON is characterized by low-pollution level. *In vivo* experiments shown that ingestion of low doses DON could induce anorexia, decrease of weight gain and changes in immune and reproductive systems ([@bib9]; [@bib40]). However, few studies have focused on the interaction between low-dose of DON and other intestinal pathogenic agents.

The gut is the most important digestive organ and the intestinal environment is complex. The gut microbiota including normal and pathogenic microorganisms as well as intakes such as nutrients and mycotoxins (Ochratoxin A \[OTA\], Zearalenone \[ZEA\] and DON) from food are the vital components in the gastrointestinal tract ([@bib8]; [@bib46]; [@bib47]). Changes of gut microbiota affect the development of intestinal diseases such as Irritable Bowel Syndrome (IBS), while mycotoxins can disrupt the gut microbiota balance. ([@bib8]). Ingestion of ZEA (40 μg/kg body weight) for 6 weeks affected microbiota diversity in porcine colon contents ([@bib41]). The combination of ZEA and DON increased amino acid metabolism of gut microbiota, which may be detrimental ([@bib41]). However, DON could also increase the potential risk of intestinal pathogens. Study confirmed that Aflatoxin and Fumonisin increased Shigatoxin-producing *E. coli* (STEC) in fecal ([@bib6]). DON could promote the porcine epidemic diarrhea virus (PEDV) infection though triggering p38-mediated autophagy which may suggest mycotoxin influences the prevalence of coronavirus and increases the risk of viral diseases ([@bib30]). According to the effects of mycotoxins on gut microbiota, we suspect that DON exacerbate the impact of diseases induced by intestinal pathogens. Lipopolysaccharide (LPS) is major pathogenic factor of gram-negative bacteria. As an endotoxin produced by bacteria, LPS is highly antigenic and cytotoxic which could cause significant increase of inflammatory response. *In vivo* experiment, LPS (5 mg/kg body weight) injection was used to construct acute kidney injury model in C57BL/6J male mice ([@bib18]). *In vitro* experiments showed that treatment with 1--10 μg/mL LPS significantly improves gene expression of inflammatory markers ([@bib7]; [@bib55]; [@bib58]). Studies showed that LPS (1 μg/mL) also induced intestinal barrier dysfunction, which suggests that LPS can induce intestinal injury ([@bib14]; [@bib56]).

According to the serious harm caused by intestinal pathogenic bacteria and contamination of mycotoxins, we should pay more attention to the combination enterotoxicity caused by bacteria and mycotoxins. The aim of this study was to explore whether low-dose nontoxic DON could impact intestinal inflammation and barrier function variety induced by bacteria, and the mechanism related to these effects. In this study, the porcine intestinal cell line IPEC-J2 cell which is the common intestinal model in the study of intestinal injury was used. LPS, the main component of cell wall of gram-negative bacteria, was used to simulate the role of the gut bacteria.

2. Materials and methods {#sec2}
========================

2.1. Cell culture and treatment {#sec2.1}
-------------------------------

IPEC-J2 was cultured in DMEM/F12 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (Gibco, USA). The cells were incubated in a 5% CO~2~ cell incubator (Thermo Scientific, USA) at 37 °C. IPEC-J2 cells were seed into 96 or 6-well plates, and treated with DON and lipopolysaccharide (LPS) (1 μg/mL) for 12 or 24 h when the confluent monolayers formed. DON, LPS and dimethyl sulfoxide (DMSO) were purchased by Sigma-Aldrich (USA).

2.2. Cell viability analysis {#sec2.2}
----------------------------

Cell viability was measured by colorimetric 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, USA) assay. In order to reduce the effect of LPS on cell viability, 1 μg/mL LPS, lower effective dose for activating inflammatory markers, was selected. Monolayers of IPEC-J2 cells were cultured in 96-well plates and then treated with different concentrations of DON (0, 1, 2, 4, 8, 16 μM) and LPS (1 μg/mL) when the confluent monolayers formed. After culturing for 12 h and 24 h, MTT was added and incubated for another 4 h. Finally, removed the medium and added 150 μL DMSO to dissolve the formazan. The absorbance was measured at 490 nm using a Microplate Reader (Bio-Rad, USA).

2.3. Lactate dehydrogenase activity {#sec2.3}
-----------------------------------

The lactate dehydrogenase (LDH) activity was detected using LDH Kits (Jiancheng, China). The assay was performed as described previously ([@bib17]).

2.4. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) {#sec2.4}
---------------------------------------------------------------------------

After the corresponding treatment on cells, the total RNA was extracted by RNAiso Plus Kit (TaKaRa, China) according to the instruction. The RNA quality was assessed by the ratio of OD260/OD280. The expressions of related genes were detected using the ABI Prism Step One Plus detection system (Applied Biosystems, USA). The expression levels of mRNA were calculated by 2^−ΔΔCT^ method and normalized with the housekeeping gene β-actin. The reverse transcription used Prime Script Ⅱ 1st Strand cDNA Synthesis Kit (TaKaRa, China) and real-time PCR was performed by SYBR Premix Ex Taq Ⅱ (TaKaRa, China) and ABI 7500 real-time PCR system (Applied Biosystems, USA). The primers used were synthesized by Sangon Biotech (Shanghai, China) ([Table 1](#tbl1){ref-type="table"} ).Table 1Gene sequence.Table 1Target geneAccession numberPrimer sequence (5′-3′)Tm (°C)TNF-α[NM_214022.1](ncbi-n:NM_214022.1){#intref0015}F: GCCCTTCCACCAACGTTTTC57.4R: CAAGGGCTCTTGATGGCAGA57.8IL-6[NM_214399.1](ncbi-n:NM_214399.1){#intref0020}F: CCTCTCCGGACAAAACTGAA57.5R: TCTGCCAGTACCTCCTTGCT57.3TGF-β[XM_021093503.1](ncbi-n:XM_021093503.1){#intref0025}F: GGACCTTATCCTGAATGCCTT57.6R: TAGGTTACCACTGAGCCACAAT56.7ZO-1[XM_021098848.1](ncbi-n:XM_021098848.1){#intref0021}F: ATGAGCAGGTCCCGTCCCAAG62.6R: GGCGGAGGCAGCGGTTTG64.2Occludin[XM_005672522.3](ncbi-n:XM_005672522.3){#intref0030}F: GACAGACTACACAACTGGCGG58.5R: TGTACTCCTGCAGGCCACTG60.2Claudin-1[NM_001244539.1](ncbi-n:NM_001244539.1){#intref0035}F: CCATCGTCAGCACCGCACTG62.5R: CGACACGCAGGACATCCACAG61.5β-actin[XM_021086047.1](ncbi-n:XM_021086047.1){#intref0040}F: CTGCGGCATCCACGAAACT58.9R: AGGGCCGTGATCTCCTTCTG59.8

2.5. Western blotting analysis {#sec2.5}
------------------------------

After corresponding treatment, monolayers of IPEC-J2 cells in 6-well plates were washed 3 times with ice-cold PBS. After washing, RIPA lysis buffer containing 1% PMSF protease inhibitor was added. Cells were broken by an ultrasonic cell disruptor, and the supernatant was collected after centrifuging at 4 °C and 12000 rpm for 15 min. The concentration of protein was detected by BCA Protein Assay Kit (Beyotime, China). The next progress of western blotting was performed as described previously ([@bib49]). Proteins were detected by specific primary antibodies: ZO-1 (AF5145, 1:1000, Affinity, China), Occludin (ab167161, 1:1000, Abcam, UK), NLRP3 (DF7438, 1:500, Affinity, China), procaspase-1 (AF5418, 1:500, Affinity, China), p65(AF1234, 1:1000, Beyotime, China), *p*p65 (AF5875, 1:1000, Beyotime, China), IκB-α (AF2176, 1:1000, Beyotime, China), LC3B (L8918, 1:1000, Sigma, USA). The secondary antibody was Anti-rabbit IgG antibody (\#7074, 1:10000, CST, USA).

2.6. Immunofluorescence {#sec2.6}
-----------------------

Monolayers of IPEC-J2 cells were cultured on glass coverslips which were placed in 12-well plates. Cells were fixed in 4% paraformaldehyde at 4 °C for 20 min after washing 3 times using PBS, and then 0.2% Triton X-100 was added for 20 min and blocked with 1% bovine serum albumin (BSA, Solarbio, China) at 37 °C for 1 h. Next, cells were incubated using specific primary antibody at 4 °C overnight, and then incubated with secondary FITC-labeled antibody (1:100, Solarbio, China). Finally, cell nuclei were stained with DAPI (Beyotime, China) at room temperature for 5 min. Images were captured using laser scanning confocal microscope (Carl Zeiss, Germany). Primary antibody was ZO-1 (13663S, 1:300, CST, USA).

2.7. LC3B^-/-^ IPEC-J2 cells construction by CRISPR/Cas9 system {#sec2.7}
---------------------------------------------------------------

The small guide RNAs (sgRNAs) were designed using Breaking-Cas online tool and synthesized (Invitrogen). The sgRNA was cloned pCas-Puro-U6 plasmid and the pCas-Puro-U6 plasmid Linear was obtained using the BbsI restriction enzyme (Thermo Fisher Scientific, USA). The plasmids containing sgRNA were transfected into IPEC-J2 cells with GeneTran III (Biomiga, USA) for 48 h, and then the transfected cells were selected using 5 μg/mL of puromycin. The selected cells were subjected to serial dilutions in 96-well plate to obtain a single cell colony. Each single colony was picked and expanded after colony formation. Genomic DNA was extracted from individual clones and sequenced to confirm the specificity of targeting.

2.8. Statistical analysis {#sec2.8}
-------------------------

The experimental data were analyzed using SPSS 19.0 for statistical analysis. Date were presented as the mean ± SEM. All experiments were performed at least three times. One-way analysis of variance (ANOVA) was used to analyze the differences for multiple groups. \*/^\#^ indicated *P* \< 0.05 and \*\*/^\#\#^ indicated *P* \< 0.01.

3. Results {#sec3}
==========

3.1. Cytotoxic effects of DON combined with LPS in IPEC-J2 cell monolayers {#sec3.1}
--------------------------------------------------------------------------

The cytotoxic effects of DON combined with LPS in IPEC-J2 monolayers were tested by MTT assay and LDH activity assay after treatments of DON (0, 1, 2, 4, 8, 16 μM) and LPS (1 μg/mL) for 12 h and 24 h, and the results were shown in [Fig. 1](#fig1){ref-type="fig"} . The result of MTT assay ([Fig. 1](#fig1){ref-type="fig"}A and C) demonstrated that cell viability was decreased with the increase of the concentration of DON. 8 μM or higher concentration of DON combined with LPS caused significant decrease of cell viability. The result of LDH assay was shown in [Fig. 1](#fig1){ref-type="fig"}B and D which demonstrated that DON promoted the release of LDH in a dose-dependent manner which reflected similar results with MTT assay. Thus, non-lethal concentration of DON (2 μM) combined with LPS (1 μg/mL) was selected for subsequent experiments.Fig. 1**Cytotoxic effect of DON combined with LPS for 12 h and 24 h of IPEC-J2 cell monolayers.** Monolayers of IPEC-J2 cells were exposed with different concentrations of DON (0, 1, 2, 4, 8, 16 μM) and LPS (1 μg/mL) for 12 h and 24 h. The cell viability was assessed by MTT assay (A for 12 h and C for 24 h) and LDH activity assay (B for 12 and D for 24 h) respectively. Date were presented as mean ± SEM (n = 6). \**P* \< 0.05 and \*\**P* \< 0.01 vs. control group.Fig. 1

3.2. Nontoxic-dose DON aggravated inflammation induced by LPS in IPEC-J2 cell monolayers {#sec3.2}
----------------------------------------------------------------------------------------

To investigate the inflammatory effects of LPS combined with nontoxic-dose DON in IPEC-J2 monolayers, cells were exposed to DON and LPS for 12 and 24 h after the confluent monolayers formed, and pro-inflammatory cytokines (IL-6 and TNF-α) and anti-inflammatory cytokine (TGF-β) were assessed by RT-qPCR. The expression of IL-6 and TNF-α mRNA in DON-LPS group were significantly increased in the 12 h and 24 h compared with that in LPS group, which were also significantly higher than that in control and DON group (*P* \< 0.05) ([Fig. 2](#fig2){ref-type="fig"} ). These results suggested that nontoxic-dose DON could aggravate the inflammation induced by LPS in IPEC-J2 cells.Fig. 2**Effects of LPS combined with nontoxic-dose DON on inflammatory cytokines of IPEC-J2 cell monolayers.** IPEC-J2 cells were exposed to DON (2 μM) and/or LPS (1 μg/mL) for 12 h and 24 h. The expression of TNF-α, IL-6 and TGF-β mRNA was measured by RT-qPCR after corresponding treatments for 12 h (A) and 24 h (B) respectively. Date were presented as mean ± SEM (n = 3). \**P* \< 0.05 and \*\**P* \< 0.01 vs. control group. ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. LPS group.Fig. 2

3.3. Nontoxic-dose DON further increased protein expression of NLRP3 and procaspase-1 induced by LPS in IPEC-J2 cell monolayers {#sec3.3}
-------------------------------------------------------------------------------------------------------------------------------

To evaluate the effects of DON and/or LPS on NLRP3 and procaspase-1, the related protein expression of IPEC-J2 monolayers after corresponding treatment was measured by western blotting. As shown in [Fig. 3](#fig3){ref-type="fig"} , exposure to DON for 24 h didn\'t affect the protein expression level of NLRP3 and procaspase-1, while the addition of LPS significantly increased (*P* \< 0.05) the protein expression of NLRP3 and procaspase-1 compared with control and DON group. In comparison with the LPS group, the combination of DON and LPS further increased NLRP3, while the expression of procaspase-1 also increased but not significantly. Therefore, nontoxic-dose DON could further promote LPS-induced protein expression level of NLRP3 and procaspase-1 in IPEC-J2 monolayers, which may reflect the activation of NLRP3 inflammasome.Fig. 3**Effects of LPS combined with nontoxic-dose DON on protein expression of NLRP3 and procaspase-1 of IPEC-J2 cell monolayers.** After corresponding treatment using DON and LPS for 24 h, the protein expression of NLRP3 and procaspase-1 of IPEC-J2 cells was measured by western blotting. Date were presented as mean ± SEM (n = 3). \**P* \< 0.05 and \*\**P* \< 0.01 vs. control group. ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. LPS group.Fig. 3

3.4. Nontoxic-dose DON aggravated tight junction disorder induced by LPS in IPEC-J2 cell monolayers {#sec3.4}
---------------------------------------------------------------------------------------------------

To investigate the intestinal epithelial barrier function changes induced by DON and/or LPS, the relative mRNA and protein expression and of tight junction was assessed by qRT-PCR and western blotting respectively. The distribution of tight junction protein ZO-1 was measured using immunofluorescence respectively after cells confluent monolayers formed. As shown in [Fig. 4](#fig4){ref-type="fig"} A and B, treatment with LPS for 12 h and 24 h significantly reduced the mRNA expression of tight junction (ZO-1, Occluidn and Claudin-1). The expression of ZO-1 and Occludin mRNA but not Claudin-1 decreased significantly in DON/LPS group compared with LPS group. Then the protein expression of ZO-1 and Occludin was assessed which showed a down-regulation after treatment of LPS and DON-LPS for 12 and 24 h, and DON combined with LPS showed more significant decrease (*P* \< 0.01) compared with LPS treatment alone ([Fig. 4](#fig4){ref-type="fig"}C and D). Compared with control and DON group, the distribution of ZO-1 was more disordered in LPS and DON-LPS groups, and the disorder of DON-LPS group was the most serious ([Fig. 4](#fig4){ref-type="fig"}E). These suggested that nontoxic-dose DON could aggravate LPS-induced damage to tight junction expression and structure.Fig. 4**Effects of LPS combined with nontoxic-dose DON on expression and distribution of tight junction proteins of IPEC-J2 cell monolayers.** After corresponding treatment using DON and LPS, the mRNA expression of ZO-1, Occludin and Claudin-1 was assessed using qRT-PCR (A for 12 h and B for 24 h). The expression of tight junction protein (ZO-1 and Occludin) of IPEC-J2 cells was measured by western blotting (C for 12 h and D for 24 h). After treatment for 24 h, the distribution of ZO-1 (green) was measured by immunofluorescence (DAPI, nucleus, blue) (E). Date were presented as mean ± SEM (n = 3). \**P* \< 0.05 and \*\**P* \< 0.01 vs. control group. ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. LPS group. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 4

3.5. Role of NF-κB (p65) signaling pathway in nontoxic-dose DON aggravated inflammation and tight junction disorder induced by LPS in IPEC-J2 cell monolayers {#sec3.5}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

The aforementioned results have confirmed that DON combined with LPS could lead to inflammation and tight junction disorder. Whether NF-κB (p65) signaling pathway, one of the main regulators on inflammation and immune response, is involved in the above reactions remains to be investigated. The effects of DON and/or LPS on NF-κB signaling pathway in IPEC-J2 cells were shown in [Fig. 5](#fig5){ref-type="fig"} A, after corresponding treatment for 24 h. DON alone didn\'t activate the NF-κB while LPS and DON/LPS treatment significantly promoted the phosphorylation of p65 and inhibited the protein expression of IκB-α ([Fig. 5](#fig5){ref-type="fig"}A). Meanwhile, we tested the distribution of p65 protein in IPEC-J2 cells by immunofluorescence assay and found that the combination of LPS and DON promoted p65 translocation into the nucleus ([Fig. 5](#fig5){ref-type="fig"}B). These results suggested that NF-κB (p65) signaling pathway was activated after treatment with DON combined with LPS in IPEC-J2 cells.Fig. 5**Role of NF-κB in inflammation and intestinal epithelial barrier dysfunction of IPEC-J2 monolayers induced by LPS combined with nontoxic-dose DON.** After corresponding treatment using DON and LPS, the expression of IκB-α, *p*p65 and p65 protein was determined by western blotting (A). The distribution of p65 inside and outside the nucleus was measured by immunofluorescence (B). Cells were immunostained with p65 (green) antibody and DAPI (nucleus, blue). After addition of inhibitor BAY 11--7082, the expression of TNF-α, IL-6 and TGF-β was measured by RT-qPCR (C) and the expression of NLRP3 (D) and tight junction protein (ZO-1 and Occludin) (E)was measured by western blotting. \**P* \< 0.05 and \*\**P* \< 0.01 vs. control group. ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. LPS group. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 5

To address whether NF-κB signaling pathway plays a key role in inflammatory reaction and tight junction disorder induced by DON combined with LPS, BAY 11--7082 (Beyotime, China), a common NF-κB inhibitor, was used to inhibit NF-κB signaling pathway. Before corresponding treatment, the confluent monolayer cells were pretreated with 2.5 μM BAY for 2 h. As shown in [Fig. 5](#fig5){ref-type="fig"}C and D, the addition of BAY 11--7082 reversed the inflammatory reaction and the expression of NLRP3 and procaspase-1 protein was also inhibited. In addition, tight junction protein downtrend induced by the union of DON and LPS was also eased ([Fig. 5](#fig5){ref-type="fig"}E). These results verified that NF-κB signaling pathway played a regulatory role in inflammatory reaction and tight junction dysfunction induced by LPS combined with nontoxic-dose DON in IPEC-J2 monolayers.

3.6. Role of LC3B in inflammation and tight junction induced by LPS combined with nontoxic-dose DON in IPEC-J2 cell monolayers {#sec3.6}
------------------------------------------------------------------------------------------------------------------------------

To further explore whether treatment with DON and LPS induces autophagy in IPEC-J2 cells, the expression of autophagy-related protein LC3B was detected by western blotting after corresponding treatment. As shown in [Fig. 6](#fig6){ref-type="fig"} A, DON combined with LPS led to a significant increase (*P* \< 0.01) in LC3B-Ⅱ expression. These results indicated that treatment with DON and LPS could promote LC3B-Ⅱ expression in IPEC-J2 confluent monolayer.Fig. 6**Role of LC3B in inflammation and intestinal epithelial barrier dysfunction of IPEC-J2 cell monolayers induced by nontoxic-dose DON and LPS.** After corresponding treatment using DON and LPS, the expression of LC3B was determined by western blotting (A). LC3B^-/-^ IPEC-J2 cell was constructed by CRISPR/Cas9 system (B). The expression of TNF-α, IL-6 and TGF-β mRNA was measured by RT-qPCR (C), and the protein expression of NLRP3 (D) and tight junction protein (ZO-1 and Occludin) (E) was measured by western blotting after corresponding treatment in IPEC-J2 cells and LC3B^-/-^ IPEC-J2 cells. \**P* \< 0.05 and \*\**P* \< 0.01 vs. IPEC-J2 control group. ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. IPEC-J2 LC3B^-/-^ control group. ^!^*P* \< 0.05 and ^!!^*P* \< 0.01 vs. IPEC-J2 DON + LPS group.Fig. 6

According to the above results, treatment of DON and LPS could increase LC3B-Ⅱ level in IPEC-J2 cells. To further investigate the role of LC3B in this cellular reaction, knockout cell line LC3B^-^ ^/-^ IPEC-J2 cell was constructed by CRISPR/Cas9 system ([Fig. 6](#fig6){ref-type="fig"}B). The expression of inflammatory cytokines in LC3B^-^ ^/-^ IPEC-J2 cells was different from that in wild type (WT) cells, mainly reflected in the increase of IL-6 and TNF-α mRNA levels, and the decrease of TGF-β mRNA level which suggested that the inflammatory responses states of two cell lines were not consistent ([Fig. 6](#fig6){ref-type="fig"}C). However, the mRNA expression of IL-6 and TGF-β in LC3B^-^ ^/-^ IPEC-J2 cells was significantly reversed while TNF-α was not compared with IPEC-J2 cells after both treatment with DON and LPS ([Fig. 6](#fig6){ref-type="fig"}C). LC3B knockout also inhibited the elevated expression of NLRP3 and procaspase-1 protein after DON and LPS treatment ([Fig. 6](#fig6){ref-type="fig"}D). At the same time, the expression of tight junction protein ZO-1 and Occludin was not affected by treatment with LPS and DON in LC3B^-^ ^/-^ IPEC-J2 cells ([Fig. 6](#fig6){ref-type="fig"}E). These results suggested that LC3B knockout could effectively alleviate the damage of DON and LPS combined application to IPEC-J2 cells, which indicated that LC3B or autophagy played an important regulatory role in inflammatory reaction and epithelial barrier dysfunction induced by LPS combined with nontoxic-dose DON in IPEC-J2 cell monolayers.

4. Discussion {#sec4}
=============

Deoxynivalenol (DON), as a wide-spread contamination mycotoxin, widely exists in feed and seriously threatens animal health. DON has been reported to induce inflammation both *in vivo* and *in vitro* ([@bib37]; [@bib61]). According to previous studies, toxic dose of DON (over 0.5 μg/mL) mainly induced inflammation in the intestinal epithelial cells ([@bib21]; [@bib26]). Acute high doses of DON (over 2.0 mg/kg feed) could cause diarrhea, vomiting and hemorrhage in animals, whereas low doses of DON (approximately 1 mg/kg feed) induced anorexia, decrease of weight gain and changes in immune and reproductive systems ([@bib9]; [@bib12]; [@bib40]). In fact, ingestion of low-dose DON (under 0.5 mg/kg feed) in animals is more common according to the contamination of DON ([@bib51]; [@bib63]). Intestine, the main target organ of DON, is a complex environment in which germ and mycotoxins interact. Chen et al. suggested that nontoxic OTA (4 μM) could promote DON-induced (4 μM) intestinal barrier dysfunction in IPEC-J2 cells ([@bib60]). Wageha et al. have found that DON (5 and 10 mg/kg feed) could facilitate the translocation of enteric microorganisms such as *E. coli* to extra-intestinal organs in broiler chickens ([@bib5]). However, the interaction and its mechanism between germ and DON are still unclear.

In this study, we focused on the effects of low-dose DON on bacteria-induced intestinal inflammation and barrier function dysfunction. Endotoxin LPS from *E. coli* was used to simulate the role of intestinal gram-negative bacteria, and the porcine intestinal cell line IPEC-J2 was used to evaluate the varieties on intestinal inflammation and barrier function.

In the present study, the nontoxic concentration of DON was selected using MTT assay and LDH activity assay. *In vitro* experiments shown that LPS (1--10 μg/mL) can induce inflammatory response, and 1 μg/mL LPS is the common dose used to induce barrier dysfunction in intestinal epithelial cells. Nontoxic concentration of DON combined with LPS was similar with DON treatment alone according to previous study, which showed 1 μg/mL LPS didn\'t affect the toxicity of DON ([@bib60]). So, 1 μg/mL LPS was selected and treatment with combination of DON (0--4 μM) and LPS (1 μg/mL) showed no cytotoxic to monolayers IPEC-J2 cells for 12 h and 24 h ([Fig. 1](#fig1){ref-type="fig"}). Therefore, 0--4 μM DON was considered as nontoxic dose on the basic treatment with LPS (1 μg/mL), and the nontoxic concentration (2 μM DON and 1 μg/mL LPS) was selected for subsequent study. The mRNA expression of pro-inflammatory cytokines (IL-6 and TNF-α) in IPEC-J2 were significantly increased, whereas anti-inflammatory cytokine TGF-β was decreased after LPS treatment alone for 12 or 24 h. The increasing or decreasing trend of related cytokines were more significant when cells were co-exposed to DON and LPS ([Fig. 2](#fig2){ref-type="fig"}). These results suggested that the addition of nontoxic-dose DON could enhance the inflammatory response induced by LPS in IPEC-J2 cells, which were similar with earlier research that LPS combined with DON could induce a certain up-regulation of the proinflammatory response in the duodenum of broiler chickens ([@bib31]). The NLRP3 inflammasome, a member of innate immune receptor NLR family which execute cellular inflammation processes, is expressed in gut epithelial cells and plays an important role in intestinal inflammation and infectious enteritis ([@bib15]; [@bib64]). Ge et al. found that the activation of NLRP3 inflammasome induced the production of proinflammatory cytokines ([@bib11]). In the present study, the protein expression of NLRP3 and procaspase-1 was increased induced by LPS, which was a common activator of NLRP3 inflammasome ([@bib52]). With the addition of nontoxic-dose DON, NLRP3 expression level but not procaspase-1 was significantly increased which demonstrated the further activation of NLPR3 was induced by nontoxic-dose DON on the basis of LPS treatment ([Fig. 3](#fig3){ref-type="fig"}). Considering the increase expressions of the important components of NLRP3 inflammasome, we estimated that the activation of NLRP3 inflammasome is involved in nontoxic-dose DON exacerbating the LPS-induced inflammatory response.

The intestinal mucosa constitutes an essential barrier which is directly related to health of human and animals, and DON has been reported to injure the intestinal barrier function according to many studies ([@bib10]; [@bib23]; [@bib38]; [@bib45]). Tight junction (TJ) is the main connection form between intestinal epithelial cells, and plays an important role in maintaining intestinal epithelial mechanical barrier ([@bib62]). Tight junction proteins, including ZO-1, Occludin and Claudins, are directly related to the function of tight junction barrier ([@bib34]; [@bib54]; [@bib57]). In the present study, ZO-1 and Occludin which could reflect the diversification of intestinal epithelial barrier were measured using western blotting and immunofluorescence to explore the expression and distribution of tight junction protein. We observed that nontoxic-dose DON treatment alone had no significant impact on the protein expression of ZO-1 and Occludin, and the distribution of ZO-1 ([Fig. 4](#fig4){ref-type="fig"}). However, nontoxic-dose DON exacerbated the decreasing mRNA and protein expression of ZO-1 and Occludin induced by LPS treatment while expression of Claudin-1 mRNA had no significant declined ([Fig. 4](#fig4){ref-type="fig"}A--D). Meanwhile, the disordered distribution of ZO-1 was more serious after co-exposed with DON and LPS compared with that induced by LPS alone ([Fig. 4](#fig4){ref-type="fig"}E). These results showed that nontoxic-dose DON aggravated intestinal epithelial barrier dysfunction induced by LPS which were consistent with earlier reports that low doses of mycotoxins could intensify the effects induced by other stimulants ([@bib43]; [@bib60]).

Next, we further studied the mechanism of the above phenomenon that nontoxic-dose DON could aggravated LPS-induced intestinal inflammation and barrier dysfunction in IPEC-J2 cell monolayers. Many studies have reported that mycotoxins could regulate inflammatory cytokines through regulating nuclear factor-κB (NF-κB) signaling pathway ([@bib48]; [@bib50]; [@bib53]; [@bib64]). In addition, NF-κB has been reported to regulate the tight junction barrier and NLRP3 inflammasome response to some extracellular stimuli ([@bib2]; Guo et al., 2019; [@bib64]). Therefore, we speculated that NF-κB signaling pathway may be associated with the aggravating effects of inflammation and barrier dysfunction induced by DON and LPS. Firstly, we confirmed that nontoxic-dose DON could further activate NF-κB (p65) signaling pathway induced by LPS, and induce migration of p65 into the nucleus ([Fig. 5](#fig5){ref-type="fig"}A and B). Then, the intestinal inflammation and tight junction disorder were relieved after the addition of NF-κB inhibitor BAY 11--7082 ([Fig. 5](#fig5){ref-type="fig"}C and E), which proved that NF-κB signaling pathway played a regulatory role in nontoxic-dose DON aggravated LPS-induced intestinal inflammation and barrier dysfunction. However, intestinal inflammation and barrier function did not return to normal level. So, we speculated that NF-κB signaling pathway is not the only pathway to regulate these varieties.

Autophagy is a critical cellular process which has been implicated in a variety of pathogenic process of mycotoxins ([@bib19]; [@bib43]) Numerous studies have highlighted the critical role of autophagy in inflammatory cytokine responses ([@bib1]; [@bib32]). Autophagy is also critical for the development and function of intestinal epithelial cells ([@bib33]; [@bib42]). However, autophagy may have different phenotypic effects in each cell type in intestinal homeostasis and inflammatory bowel diseases ([@bib24]). Considering the intertwined relationship between autophagy, inflammation and intestinal injury, we suspected whether autophagy is involved in the regulation of cellular reaction induced by DON and LPS in IPEC-J2 cells. In this study, we focused on one of autophagy-related proteins LC3B and an increasing expression level of LC3B-Ⅱ was observed after treatment with LPS or DON/LPS in IPEC-J2 cell monolayers ([Fig. 6](#fig6){ref-type="fig"}A). Li et al. described that inhibition of autophagy could reduce intestinal injury induced by I/R ([@bib27]). And Yamoto et al. found that inhibiting autophagy may be a new strategy for treating intestinal diseases ([@bib59]). To further investigate the role of LC3B, we constructed LC3B^-^ ^/-^ IPEC-J2 cell lines ([Fig. 6](#fig6){ref-type="fig"}B). As shown in [Fig. 6](#fig6){ref-type="fig"}C, knock-out LC3B could relieve the inflammatory response. Meanwhile, the protein expression of NLRP3 and procaspase-1 was also decreased on LC3B^-^ ^/-^ IPEC-J2 after corresponding treatment compared with WT cells ([Fig. 6](#fig6){ref-type="fig"}D). In addition, knock-out LC3B basically eliminated the impact on the tight junction induced by LPS combined with nontoxic-dose DON in IPEC-J2 cell monolayers ([Fig. 6](#fig6){ref-type="fig"}E). Taken together, the results demonstrated that the accumulation of LC3B played a negative regulatory role in nontoxic-dose DON aggravated LPS-induced intestinal inflammation and barrier dysfunction.

5. Conclusion {#sec5}
=============

In conclusion, our study demonstrated that nontoxic-dose DON could aggravate the cellular inflammation response and tight junction dysfunction induced by LPS in IPEC-J2 cell monolayers. We also confirmed that NF-κB (p65) signaling pathway and autophagy-related protein LC3B played a regulatory role in nontoxic-dose DON aggravated LPS-induced intestinal inflammation and tight junction disorder. Therefore, these findings indicate nontoxic-dose mycotoxins could exacerbate the negative effects of intestinal bacteria and increase vigilance against low concentration of mycotoxin contamination.
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